HTG Molecular Diagnostics (HTGM) Getting Somewhat Favorable Media Coverage, Accern Reports

News coverage about HTG Molecular Diagnostics (NASDAQ:HTGM) has trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.8041765972858 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Shares of HTG Molecular Diagnostics (HTGM) opened at $5.06 on Friday. HTG Molecular Diagnostics has a 52-week low of $1.20 and a 52-week high of $13.25. The firm has a market cap of $131.71, a P/E ratio of -1.98 and a beta of 2.04.

Several brokerages have recently weighed in on HTGM. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Thursday, January 25th. Canaccord Genuity upped their price target on shares of HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.31.

TRADEMARK VIOLATION WARNING: “HTG Molecular Diagnostics (HTGM) Getting Somewhat Favorable Media Coverage, Accern Reports” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/18/htg-molecular-diagnostics-htgm-getting-somewhat-favorable-media-coverage-accern-reports.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Insider Buying and Selling by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply